Literature DB >> 11863476

Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy.

Amy T Calabrese1, Kim C Coley, Stacey V DaPos, Dennis Swanson, R Harsha Rao.   

Abstract

BACKGROUND: The risk of lactic acidosis during metformin therapy is linked to specific and well-documented conditions that constitute contraindications or precautions to use of the agent. We conducted a retrospective evaluation of metformin use to determine whether prescribing practices are in accord with published contraindications and precautions.
METHODS: All patients admitted to the hospital during a 6-month period who received at least 1 dose of metformin were identified through hospital pharmacy records. Patient demographics and clinical characteristics were then evaluated to determine whether metformin was prescribed to patients possessing any of the risk factors associated with development of lactic acidosis.
RESULTS: We identified 263 hospitalizations involving 204 patients who received at least 1 dose of metformin during inpatient admission. Patients had at least 1 absolute contraindication to metformin therapy in 71 admissions (27%). In 29 (41%) of these 71 admissions, treatment with metformin continued despite the contraindication. The most common contraindication, elevated serum creatinine concentration, was present or developed during 32 admissions (12%); however, metformin use was appropriately discontinued in only 8 (25%) of these 32 patients. Of the precautions against metformin use, concomitant administration of cationic agents was the most common, occurring in 97 admissions (37%).
CONCLUSIONS: Many patients are treated with metformin despite having clinical conditions that place them at risk for developing lactic acidosis. To minimize this risk, it is essential that prescribers develop a better understanding of the prescribing guidelines for metformin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11863476     DOI: 10.1001/archinte.162.4.434

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  31 in total

1.  [Metformin-associated lactic acidosis with acute renal failure in type 2 diabetes mellitus].

Authors:  Heinrich Lothholz
Journal:  Med Klin (Munich)       Date:  2002-07-15

Review 2.  Management of hyperglycemia in hospitalized patients.

Authors:  Dawn Smiley; Guillermo E Umpierrez
Journal:  Ann N Y Acad Sci       Date:  2010-10-29       Impact factor: 5.691

Review 3.  Metformin's contraindications should be contraindicated.

Authors:  James McCormack; Kevin Johns; Hugh Tildesley
Journal:  CMAJ       Date:  2005-08-30       Impact factor: 8.262

4.  Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system.

Authors:  Nina Langoth; Hermann Kahlbacher; Gudrun Schöffmann; Ivo Schmerold; Maximilian Schuh; Sonja Franz; Peter Kurka; Andreas Bernkop-Schnürch
Journal:  Pharm Res       Date:  2006-01-19       Impact factor: 4.200

Review 5.  Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

Authors:  Silvio E Inzucchi; Kasia J Lipska; Helen Mayo; Clifford J Bailey; Darren K McGuire
Journal:  JAMA       Date:  2014 Dec 24-31       Impact factor: 56.272

6.  Impact of metformin use on the prognostic value of lactate in sepsis.

Authors:  Jeffrey P Green; Tony Berger; Nidhi Garg; Alison Suarez; Yolanda Hagar; Michael S Radeos; Edward A Panacek
Journal:  Am J Emerg Med       Date:  2012-03-16       Impact factor: 2.469

7.  Electronic medical record prompts for lab orders in patients initiating statins.

Authors:  D G Carroll; C Alexander; E A Radford; J Leeper; D N Carroll
Journal:  Appl Clin Inform       Date:  2011-03-16       Impact factor: 2.342

8.  The Association between Metformin Therapy and Lactic Acidosis.

Authors:  Isabelle H S Kuan; Ruth L Savage; Stephen B Duffull; Robert J Walker; Daniel F B Wright
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

Review 9.  Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?

Authors:  A A Tahrani; G I Varughese; J H Scarpello; F W F Hanna
Journal:  BMJ       Date:  2007-09-08

10.  Use of renal risk drugs in patients with renal impairment.

Authors:  Hilde Holm; Kirsti Bjerke; Lone Holst; Liv Mathiesen
Journal:  Int J Clin Pharm       Date:  2015-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.